(Reuters) – The U.S. Food and Drug Administration has extended its review of Regeneron Pharmaceuticals Inc’s application for the full approval of its COVID-19 antibody therapy by three months, the U.S. drugmaker said on Thursday.
Regeneron invented the antibody cocktail and is collaborating with Roche, which is primarily responsible for development and distribution outside the United States.
(Reporting by Amruta Khandekar in Bengaluru; Editing by Maju Samuel)
